Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tempus
Biotech
Tempus AI in line for $200M from AstraZeneca cancer model deal
Tempus has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based model that could be used to develop new cancer drugs.
James Waldron
Apr 23, 2025 9:01am
Illumina, Tempus team up to expand DNA profiling beyond cancer
Apr 15, 2025 11:30am
Tempus clocks FDA approval for 648-gene cancer test
May 8, 2023 8:05am
GSK pays Tempus $70M to expand access to patient data library
Oct 18, 2022 8:05am
Tempus picks Lilly to bring genomic tests to NSCLC patients
Jun 9, 2022 1:04pm
